These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 31612482)

  • 21. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
    Hirata K; Sakai F; Takeshima T; Imai N; Matsumori Y; Yoshida R; Numachi Y; Peng C; Mikol DD; Cheng S
    J Headache Pain; 2021 Sep; 22(1):110. PubMed ID: 34537006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
    Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
    JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
    Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
    Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Reuter U; Ehrlich M; Gendolla A; Heinze A; Klatt J; Wen S; Hours-Zesiger P; Nickisch J; Sieder C; Hentschke C; Maier-Peuschel M
    Cephalalgia; 2022 Feb; 42(2):108-118. PubMed ID: 34743579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
    Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
    Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing and durability of response to erenumab in patients with episodic migraine.
    McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
    Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
    Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M
    Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 33. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
    Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Lipton RB; Dodick DW; Kudrow D; Reuter U; Tenenbaum N; Zhang F; Lima GPDS; Chou DE; Mikol DD
    Cephalalgia; 2021 Dec; 41(14):1458-1466. PubMed ID: 34407654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
    Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
    Brandes JL; Diener HC; Dolezil D; Freeman MC; McAllister PJ; Winner P; Klatt J; Cheng S; Zhang F; Wen S; Ritter S; Lenz RA; Mikol DD
    Cephalalgia; 2020 Jan; 40(1):28-38. PubMed ID: 31816249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
    Ashina M; Kudrow D; Reuter U; Dolezil D; Silberstein S; Tepper SJ; Xue F; Picard H; Zhang F; Wang A; Zhou Y; Hong F; Klatt J; Mikol DD
    Cephalalgia; 2019 Dec; 39(14):1798-1808. PubMed ID: 31707815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.